IP Library › Granted Patent US 12,606,522
Granted Patent B2
US 12,606,522 · App. 18/742,992 · Granted Apr 21, 2026

Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives

Inventors: Julie Farand (San Mateo, CA); Joshua A. Kaplan (Foster City, CA); Gregory Notte (Redwood City, CA); Casey Lockwood Olen (Belmont, CA); Michael Sangi (San Mateo, CA); David Sperandio (Palo Alto, CA)
Assignee: ORSOBIO, INC.
C07C323/25A61K31/18A61P1/16A61P3/10C07C311/08C07C311/13C07C311/14C07C311/21C07C311/29C07C311/39C07C311/46C07C313/06C07C323/30C07C323/31C07D205/04C07D207/48C07D213/89C07D231/18C07D235/00C07D239/26C07D257/04C07D275/02C07D277/36C07D279/12C07D295/116C07D305/08C07D309/08C07D335/02C07D451/02C07D493/08C07F9/5022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,522
App. No.
18/742,992
Granted
Apr 21, 2026
Kind
B2
Abstract

Provided is a compound of Formula (I): wherein the variable groups are defined herein.

Claims (142)

1 . A method of treating a metabolic disorder comprising administering to a patient in need thereof, an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, wherein:

Q is —S(O) 2 —;

R 1 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —NR 13 R 13 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is optionally further substituted with one or more R 11 groups;

R 11 is selected from a group consisting of: hydroxyl, oxo, halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —P(O)R 14 R 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —SH, —S(O) 0-2 R 14 , —S(O) 1-2 NR 13 R 13 , —SF 5 , —NO 2 , —NR 13 R 13 , —NR 13 SO 2 R 14 , —OS(O) 2 R 14 , —C(O)OR 14 , —C(O)R 14 , —NR 13 C(O)OR 14 , —NR 13 C(O)NR 13 R 13 , —NR 13 S(O) 2 NR 13 R 13 , and —C(O)NR 13 R 13 , wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 9 groups;

each R 9 is independently selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —NR 13 R 13 , —NR 13 C(O)OR 14 , —OS(O) 2 R 14 —C(O)OR 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —S(O) 0-2 R 14 , —S(O) 1-2 NR 13 R 13 , —C(O)NR 13 R 13 , —NR 13 SO 2 R 14 , —C(O)R 14 , —NR 13 C(O)NR 13 R 13 , —NR 13 S(O) 2 NR 13 R 13 , SF 5 and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 16 groups;

each R 13 is independently selected from the group consisting of —H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are optionally substituted with one or more R 15 groups,

each R 14 is independently selected from the group consisting of: C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are optionally substituted with one or more R 15 groups,

each R 15 is independently selected from the group consisting of —H, halo, —CN, —OH, oxo, —NO 2 , —SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O)(NH)R 16 , —S(O)(NR 8 )R 16 , —S(O)(NH)NR 16 R 16 , —S(O)(NR 8 )NR 16 R 16 , —S(O) 0-2 R 16 , —S(O) 2 NH 2 , —NH 2 , —S(O) 2 NR 16 R 16 , C(O)R 16 , —C(O)NR 16 R 16 and C(O)OR 16 , wherein said 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 16 groups,

each R 16 is independently selected from halo, —CN, —OH, —NH 2 , oxo, —NO 2 , —SF 5 , C 1-3 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, thiohaloalkyl, sulfonylalkyl, sulfonylhaloalkyl, sulfonylcycloalkyl, 3-6 membered cycloalkyl, —C(O)NH 2 , and —S(O) 2 NH 2 ,

R 2 is selected from the group consisting of: —H, —CN, —F, —Cl, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 heteroalkyl, C 1-3 alkoxy and C 1-3 haloalkoxy;

each R 3 and R 4 is independently selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —SH, —NR 13 R 13 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , —NR 13 C(O)OR 14 , tri-C 1-4 alkylsilyl, —C(O)R 14 , —C(O)OR 14 , —C(O)NR 13 R 13 , and —NO 2 , wherein C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl are optionally further substituted with one or more R 9 groups;

R 5 is selected from a group consisting of: —H, —CN, —F, —Cl, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 heteroalkyl, C 1-3 alkoxy and C 1-3 haloalkoxy;

wherein R 2 and R 3 , or R 3 and R 4 , or R 4 and R 5 can optionally join, together with the atoms to which they are attached, to form a 5-6 membered cycloalkyl, a 5-6 membered heterocyclyl, phenyl, or a 5-6 membered heteroaryl, each such cyclic groups respectively fused to the phenyl to which they are attached, and each optionally substituted with one or more R 9 groups;

R 6 is a 5-10 membered carbobicyclic ring, wherein the 5-10 membered carbobicyclic ring, may be fused, bridged or spiro, and wherein the 5-10 membered carbobicyclic ring, is substituted with one or more R 7 ;

R 7 is selected from the group consisting of: —H, halo, —CN, oxo, —OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, —S(O) 0-2 R 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —SH, —NR 13 R 13 , —P(O)R 14 R 14 , —C(O)OH, —C(O)OR 14 , —C(O)NR 13 R 13 , —S(O) 2 NR 13 R 13 , —C(O)R 14 , 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-12 membered cycloalkyl is optionally substituted with one or more R 15 ; and n is 1, 2, or 3;

R 8 is selected from the group consisting of: C 1-6 alkyl, —C(O)R 14 , 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 4-12 membered heterocyclyl, —C(O)OR 14 , —C(O)NR 13 R 13 , and —SO 2 R 14 , wherein each of the C 1-6 alkyl, —C(O)R 14 , 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl is optionally substituted with halo, —CN, oxo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, —S(O) 1-2 R 14 , —S(O) 2 NR 13 R 13 , —NO 2 , —SF 5 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, —NR 13 R 13 , —C(O)OR 14 , C 1-6 heteroalkyl, 3-6 membered cycloalkyl optionally substituted with one or more R 16 , 4-12 membered heterocyclyl optionally substituted with one or more R 16 , 6-10 membered aryl optionally substituted with one or more R 16 , or 5-10 membered heteroaryl optionally substituted with one or more R 16 ;

subject to the provisos that:

(i) when R 6 is a C 8-10 carbobicyclic ring, and both R 3 and R 7 are H,

then R 4 is selected from the group consisting of: C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl, 7-12 membered monocyclic heterocyclyl, —SF 5 , —NR 13 R 13 , —NR 13 C(O)OR 14 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , tri-C 1-4 alkylsilyl, —C(O)R 14 , —C(O)OR 14 , —C(O)NR 13 R 13 , —S(O) 0-2 R 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —SH and —NO 2 , wherein each of the C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl and 7-12 membered monocyclic heterocyclyl is optionally substituted with one or more R 9 ; 5-6 membered heterocyclyl optionally substituted with R 17 ; and 8-10 membered bicyclic heterocyclyl optionally substituted with one or more R 18 ;

(ii) when R 6 is a C 6 -C 7 carbobicyclic ring, and R 7 is H or methyl,

then R 3 is selected from the group consisting of: halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 14 , —S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —SH, —NR 13 R 13 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , —NR 13 C(O)OR 14 , tri-C 1-4 alkylsilyl, —C(O)R 14 , —C(O)OR 14 , —C(O)NR 13 R 13 , and —NO 2 , wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally further substituted with one or more R 9 groups;

wherein R 17 is selected from the group consisting of —OH, oxo, —CN, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 14 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , —NR 13 C(O)OR 14 , —C(O)R 14 , —C(O)OR 14 and —C(O)NR 13 R 13 ,

and wherein R 18 is selected from the group consisting of C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 14 , —NR 13 R 13 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , —NR 13 C(O)OR 14 , —C(O)R 14 , —C(O)OR 14 and —C(O)NR 13 R 13 .

2 . The method of claim 1 , wherein R 1 is selected from the group consisting of: C 1-6 alkyl, —NR 13 R 13 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is further substituted with one or more R 11 groups.

3 . The method of claim 1 , wherein R 2 is selected from the group consisting of: —H, —CN, —F, methyl, methoxy and C 1 haloalkoxy.

4 . The method of claim 3 , wherein R 2 is selected from the group consisting of: —H and —F.

5 . The method of claim 1 , wherein R 4 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —SF 5 , —S(O) 0-2 R 14 , S(O)(NH)R 14 , —S(O)(NR 8 )R 14 , —S(O)(NH)NR 13 R 13 , —S(O)(NR 8 )NR 13 R 13 , —NR 13 R 13 , —NR 13 SO 2 R 14 , —NR 13 S(O) 2 NR 13 R 13 , —NR 13 C(O)NR 13 R 13 , —NR 13 C(O)OR 14 , —C(O)R 14 , —C(O)OR 14 , —C(O)NR 13 R 13 , and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, is further substituted with one or more R 9 groups.

6 . The method of claim 5 , wherein R 4 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —S(O) 0-2 R 14 , —C(O)R 14 , —SF 5 , —NO 2 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 14 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, are optionally substituted with one or more R 15 groups, and R 15 is independently selected from the group consisting of halo, —CN, and —OH.

7 . The method of claim 6 , wherein R 4 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —SR 14 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 14 is a C 1-3 haloalkyl.

8 . The method of claim 1 , wherein R 3 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, 6-10 membered aryl, 4-12 membered heterocyclyl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —S(O) 0-2 R 14 , —NO 2 , and —SF 5 , wherein said C 1-6 alkyl, 6-10 membered aryl, 4-12 membered heterocyclyl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl is optionally further substituted with one or more R 9 groups.

9 . The method of claim 8 , wherein R 3 selected from the group consisting of: —H, —F, —Cl, —OH, —CN, C 1-6 alkyl, 4-12 membered heterocyclyl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —SR 14 , and —SF 5 , wherein said C 1-6 alkyl, C 1-6 alkoxy, C 3-12 cycloalkyl, 4-12 membered heterocyclyl, and 5-10 membered heteroaryl is optionally substituted with one or more R 9 , and R 14 is C 1-3 haloalkyl.

10 . The method of claim 1 , wherein R 5 is selected from the group consisting of: —H, —F, and methyl.

11 . A method of treating a metabolic disorder comprising administering to a patient in need thereof, an effective amount of a compound of Formula II:

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, wherein:

x, y, and z are independently 1, 2, 3, or 4,

Q is —S(O) 2 ;

R 21 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —NR 33 R 33 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is optionally further substituted with one or more R 31 groups;

R 31 is selected from the group consisting of: hydroxyl, oxo, halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —P(O)R 34 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —SH, —S(O) 0-2 R 34 , —S(O) 1-2 NR 33 R 33 , —SF 5 , —NO 2 , —NR 33 R 33 , —NR 33 SO 2 R 34 , —OS(O) 2 R 34 , —C(O)OR 34 , —C(O)R 34 , —NR 33 C(O)OR 34 , —NR 33 C(O)NR 33 R 33 , —NR 33 S(O) 2 NR 33 R 33 , and —C(O)NR 33 R 33 , wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 29 groups;

each R 29 is independently selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —NR 33 R 33 , —NR 33 C(O)OR 34 , —OS(O) 2 R 34 —C(O)OR 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —S(O) 0-2 R 34 , —S(O) 1-2 NR 33 R 33 , —C(O)NR 33 R 33 , —NR 33 SO 2 R 34 , —C(O)R 34 , —NR 33 C(O)NR 33 R 33 , —NR 33 S(O) 2 NR 33 R 33 , —SF 5 , and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 36 ;

each R 33 is independently selected from the group consisting of —H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are optionally substituted with one or more R 35 groups;

each R 34 is independently selected from the group consisting of: C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are optionally substituted with one or more R 35 groups;

each R 35 is independently selected from the group consisting of —H, halo, —CN, —OH, oxo, —NO 2 , —SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O)(NH)R 36 , —S(O)(NR 28 )R 36 , —S(O)(NH)NR 36 R 36 , —S(O)(NR 28 )NR 36 R 36 , —S(O) 0-2 R 36 , —S(O) 2 NH 2 , —NH 2 , —S(O) 2 NR 36 R 36 , C(O)R 36 , —C(O)NR 36 R 36 and C(O)OR 36 , wherein said 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 36 groups;

each R 36 is independently selected from halo, —CN, —OH, —NH 2 , oxo, —NO 2 , —SF 5 , C 1-3 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, thiohaloalkyl, sulfonylalkyl, sulfonylhaloalkyl, sulfonylcycloalkyl, 3-6 membered cycloalkyl, —C(O)NH 2 and —S(O) 2 NH 2 ;

R 22 is selected from the group consisting of: —H, —CN, —F, —Cl, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 heteroalkyl, C 1-3 alkoxy and C 1-3 haloalkoxy;

each R 23 and R 24 is independently selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —SH, —NR 33 R 33 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , —NR 33 C(O)OR 34 , tri-C 1-4 alkylsilyl, —C(O)R 34 , —C(O)OR 34 , —C(O)NR 33 R 33 , and —NO 2 , wherein C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl are optionally further substituted with one or more R 29 groups;

wherein R 22 and R 23 , or R 23 and R 24 can optionally join, together with the atoms to which they are attached, to form a 5-6 membered cycloalkyl, a 5-6 membered heterocyclyl, phenyl, or a 5-6 membered heteroaryl, each such cyclic groups respectively fused to the phenyl to which they are attached, and each optionally substituted with one or more R 29 groups;

R 27 is selected from the group consisting of: —H, halo, —CN, oxo, —OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, —S(O) 0-2 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —NR 33 R 33 , —P(O)R 34 R 34 , —C(O)OH, —C(O)OR 34 , —C(O)NR 33 R 33 , —S(O) 2 NR 33 R 33 , —C(O)R 34 , 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-12 membered cycloalkyl is optionally substituted with one or more R 35 ;

R 28 is selected from the group consisting of: C 1-6 alkyl, —C(O)R 34 , 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 4-12 membered heterocyclyl, —C(O)OR 34 , —C(O)NR 33 R 33 , and —SO 2 R 34 , wherein each of the C 1-6 alkyl, 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl is optionally substituted with halo, —CN, oxo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, —S(O) 1-2 R 34 , —S(O) 2 NR 33 R 33 , —NO 2 , —SF 5 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, —NR 33 R 33 , —C(O)OR 34 , C 1-6 heteroalkyl, 3-6 membered cycloalkyl optionally substituted with one or more R 36 , 4-12 membered heterocyclyl optionally substituted with one or more R 36 , 6-10 membered aryl optionally substituted with one or more R 36 , or 5-10 membered heteroaryl optionally substituted with one or more R 36 ;

subject to the provisos that:

(i) when x+y+z is 6 to 10, and both R 23 and R 27 are H, then R 24 is selected from the group consisting of: C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl, 7-12 membered monocyclic heterocyclyl, —SF 5 , —NR 33 R 33 , —NR 33 C(O)OR 34 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , tri-C 1-4 alkylsilyl, —C(O)R 34 , —C(O)OR 34 , —C(O)NR 33 R 33 , —S(O) 0-2 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —SH and —NO 2 , wherein each of the C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl and 7-12 membered monocyclic heterocyclyl is optionally substituted with one or more R 29 ; 5-6 membered heterocyclyl optionally substituted with R 37 ; and 8-10 membered bicyclic heterocyclyl optionally substituted with one or more R 38 ; and

(ii) when x+y+z is 4 or 5, and R 27 is —H or methyl, R 23 is selected from the group consisting of: halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —SH, —NR 33 R 33 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , —NR 33 C(O)OR 34 , tri-C 1-4 alkylsilyl, —C(O)R 34 , —C(O)OR 34 , —C(O)NR 33 R 33 , and —NO 2 , wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl are optionally further substituted with one or more R 29 groups;

wherein R 37 is selected from the group consisting of —OH, oxo, —CN, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 34 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , —NR 33 C(O)OR 34 , —C(O)R 34 , —C(O)OR 34 and —C(O)NR 33 R 33 ;

and wherein R 38 is selected from the group consisting of C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 34 , —NR 33 R 33 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , —NR 33 C(O)OR 34 , —C(O)R 34 , —C(O)OR 34 and —C(O)NR 33 R 33 .

12 . The method of claim 11 , wherein R 21 is selected from a group consisting of: C 1-6 alkyl, —NR 33 R 33 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is further substituted with one or more R 31 groups.

13 . The method of claim 11 , wherein R 22 is selected from the group consisting of: —H, —CN, —F, methyl, C 1 haloalkyl, C 1-3 heteroalkyl, methoxy and C 1 haloalkoxy.

14 . The method of claim 13 , wherein R 22 is selected from the group consisting of: —H, —CN, —F, and methyl.

15 . The method of claim 11 , wherein R 24 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —SF 5 , —S(O) 0-2 R 34 , —S(O)(NH)R 34 , —S(O)(NR 28 )R 34 , —S(O)(NH)NR 33 R 33 , —S(O)(NR 28 )NR 33 R 33 , —NR 33 R 33 , —NR 33 SO 2 R 34 , —NR 33 S(O) 2 NR 33 R 33 , —NR 33 C(O)NR 33 R 33 , —NR 33 C(O)OR 34 , —C(O)R 34 , —C(O)OR 34 , —C(O)NR 33 R 33 , and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, is further substituted with one or more R 29 groups.

16 . The method of claim 15 , wherein R 24 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, S(O) 0-2 R 34 , —C(O)R 34 , —NO 2 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 34 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, is optionally substituted with one or more R 35 groups, and R 35 is independently selected from the group consisting of halo, —CN and —OH.

17 . The method of claim 16 , wherein R 24 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —SR 34 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 34 is a C 1-3 haloalkyl.

18 . A method of treating a metabolic disorder comprising administering to a patient in need thereof, an effective amount of a compound of Formula III:

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, wherein:

Q is —S(O) 2 —;

R 41 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —NR 53 R 53 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is optionally further substituted with one or more R 51 groups;

R 51 is selected from the group consisting of: hydroxyl, oxo, halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —P(O)R 54 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , —SF 5 , —NO 2 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —OS(O) 2 R 54 , —C(O)OR 54 , —C(O)R 54 , —NR 53 C(O)OR 54 , —NR 53 C(O)NR 53 R 53 , —NR 53 S(O) 2 NR 53 R 53 , and —C(O)NR 53 R 53 , wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 49 groups;

each R 49 is independently selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —NR 53 R 53 , —NR 53 C(O)OR 54 , —OS(O) 2 R 54 —C(O)OR 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , —C(O)NR 53 R 53 , —NR 53 SO 2 R 54 , —C(O)R 14 , —NR 53 C(O)NR 53 R 53 , —NR 53 S(O) 2 NR 53 R 53 , —SF 5 , and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with R 56 ;

each R 53 is independently selected from the group consisting of —H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl is optionally substituted with one or more R 5 groups;

each R 54 is independently selected from the group consisting of: C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl is optionally substituted with one or more R 55 groups;

each R 55 is independently selected from —H, halo, —CN, —OH, oxo, —NO 2 , —SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O)(NH)R 56 , —S(O)(NR 48 )R 56 , —S(O)(NH)NR 56 R 56 , —S(O)(NR 48 )NR 56 R 56 , —S(O) 0-2 R 56 , —S(O) 2 NH 2 , —NH 2 , —S(O) 2 NR 56 R 56 , C(O)R 56 , —C(O)NR 56 R 56 and C(O)OR 56 , wherein said 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 56 groups;

each R 56 is independently selected from the group consisting of halo, —CN, —OH, —NH 2 , oxo, —NO 2 , —SF 5 , C 1-3 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, thiohaloalkyl, sulfonylalkyl, sulfonylhaloalkyl, sulfonylcycloalkyl, 3-6 membered cycloalkyl, —C(O)NH 2 and —S(O) 2 NH 2 ;

R 42 is selected from the group consisting of: —H, —CN, —F, —Cl, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 heteroalkyl, C 1-3 alkoxy and C 1-3 haloalkoxy;

each R 43 and R 44 is independently selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —SH, —S(O) 1-2 NR 53 R 53 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 53 C(O)NR 53 R 53 , —NR 53 C(O)OR 54 , tri-C 1-4 alkylsilyl, —C(O)R 54 , —C(O)OR 54 , —C(O)NR 53 R 53 , and —NO 2 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally further substituted with one or more R 49 groups;

wherein R 42 and R 43 , or R 43 and R 44 optionally join, together with the atoms to which they are attached, to form a 5-6 membered cycloalkyl, a 5-6 membered heterocyclyl, phenyl, or a 5-6 membered heteroaryl, each such cyclic groups respectively fused to the phenyl to which they are attached, and each optionally substituted with one or more R 49 groups;

R 47 is selected from the group consisting of: —H, halo, —CN, —OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, —S(O) 0-2 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —SH, —NR 53 R 53 , —P(O)R 54 R 54 , —C(O)OH, —C(O)OR 54 , —C(O)NR 53 R 53 , —S(O) 2 NR 53 R 53 , —C(O)R 54 , 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-12 membered cycloalkyl is optionally substituted with one or more R 55 ;

R 48 is selected from the group consisting of: C 1-6 alkyl, —C(O)R 54 , 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 4-12 membered heterocyclyl, C(O)OR 54 , C(O)NR 53 R 53 , and SO 2 R 54 , wherein each of C 1-6 alkyl, 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl is optionally substituted with halo, —CN, oxo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, —S(O) 1-2 R 54 , —S(O) 2 NR 53 R 53 , —NO 2 , —SF 5 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, —NR 53 R 53 , —C(O)OR 54 , C 1-6 heteroalkyl, 3-6 membered cycloalkyl optionally substituted with R 56 , 4-12 membered heterocyclyl optionally substituted with one or more R 56 , 6-10 membered aryl optionally substituted with one or more R 56 , or 5-10 membered heteroaryl optionally substituted with one or more R 56 ;

subject to the proviso that:

when both R 43 and R 47 are H, then R 44 is selected from the group consisting of: C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl, 7-12 membered monocyclic heterocyclyl, —SF 5 , —NR 53 R 53 , —NR 53 C(O)OR 54 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 5 C(O)NR 5 R 5 , tri-C 1-4 alkylsilyl, —C(O)R 54 , —C(O)OR 54 , —C(O)NR 53 R 53 , —S(O) 0-2 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —SH and —NO 2 , wherein each of the C 7-12 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 4-membered heterocyclyl, 7-membered heterocyclyl and 7-12 membered monocyclic heterocyclyl are optionally substituted with one or more R 49 ; 5-6 membered heterocyclyl optionally substituted with R 57 ; and 8-10 membered bicyclic heterocyclyl optionally substituted with one or more R 51 ;

wherein R 57 is selected from the group consisting of: —OH, oxo, —CN, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 54 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 53 C(O)NR 53 R 53 , —NR 53 C(O)OR 54 , —C(O)R 54 , —C(O)OR 54 and —C(O)NR 53 R 53 ,

and wherein R 51 is selected from the group consisting of: C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O) 0-2 R 54 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 53 C(O)NR 53 R 53 , —NR 53 C(O)OR 54 , —C(O)R 54 , —C(O)OR 54 and —C(O)NR 53 R 53 .

19 . The method of claim 18 , wherein R 47 is selected from the group consisting of —H, halo, —CN, —OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, —S(O) 0-2 R 4 , —S(O)(NH)R 14 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —NR 53 R 53 , —C(O)OH, —C(O)OR 54 , —C(O)NR 53 R 53 , —S(O) 2 NR 53 R 53 , —C(O)R 54 , 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-12 membered cycloalkyl is optionally substituted with one or more R 55 .

20 . The method of claim 18 , wherein R 47 is selected from the group consisting of —H, halo, —CN, —OH, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —S(O) 0-2 R 54 , —C(O)OH, —C(O)OR 54 , —C(O)NR 53 R 53 , —S(O) 2 NR 53 R 53 , —C(O)R 54 , 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-6 membered cycloalkyl is optionally substituted with one or more R 55 .

21 . The method of claim 18 , wherein R 47 is selected from the group consisting of —H, halo, —CN, —OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, and 6-10 membered aryl, wherein each of said 6-10 membered aryl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, and C 1-6 heteroalkyl is optionally substituted with one or more R 55 , wherein R 55 is selected from the group consisting of: halo, —CN, —NO 2 , —SF 5 , C 1-3 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy.

22 . The method of claim 18 , wherein R 41 is selected from the group consisting of: C 1-6 alkyl, —NR 53 R 53 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is further optionally substituted with one or more R 51 groups.

23 . The method of claim 18 , wherein R 51 is selected from the group consisting of: hydroxyl, oxo, halo, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , —SF 5 , —NO 2 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —C(O)OR 54 , —C(O)R 54 , —NR 53 C(O)OR 54 , and —C(O)NR 53 R 53 , wherein each C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 49 groups.

24 . The method of claim 18 , wherein each R 49 is independently selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-3 alkyl, C 1-3 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —NR 53 R 53 , —C(O)OR 54 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , —C(O)NR 53 R 53 , —NR 53 SO 2 R 54 , —C(O)R 54 , —SF 5 , and —NO 2 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, and 3-6 membered cycloalkyl, is optionally substituted with —CN, or one or more halo.

25 . The method of claim 18 , wherein R 42 is selected from the group consisting of: —H, —CN, —F, methyl, C 1 haloalkyl, C 1-3 heteroalkyl, methoxy and C 1 haloalkoxy.

26 . The method of claim 18 , wherein R 42 is selected from the group consisting of: —H and —F.

27 . The method of claim 18 , wherein R 44 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —SF 5 , —S(O) 0-2 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 53 C(O)NR 53 R 53 , —NR 53 C(O)OR 54 , —C(O)R 54 , —C(O)OR 54 , —C(O)NR 53 R 53 , and —NO 2 , wherein each C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl is further substituted with one or more R 49 groups.

28 . The method of claim 18 , wherein R 44 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —S(O) 0-2 R 54 , —NO 2 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 54 is selected from the group consisting of C 1-6 alkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, is optionally substituted with one or more R 55 groups, and R 55 is independently selected from halo, —CN, —OH, and oxo.

29 . The method of claim 18 , wherein R 44 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —SR 54 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 54 is C 1-3 haloalkyl.

30 . The method of claim 18 , wherein R 43 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-12 cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 54 , —S(O)(NH)R 54 , —S(O)(NR 48 )R 54 , —S(O)(NH)NR 53 R 53 , —S(O)(NR 48 )NR 53 R 53 , —NR 53 R 53 , —NR 53 SO 2 R 54 , —NR 53 S(O) 2 NR 53 R 53 , —NR 53 C(O)NR 53 R 53 , —NR 53 C(O)OR 54 , —C(O)R 54 , —C(O)OR 54 , —C(O)NR 53 R 53 , and —NO 2 , wherein the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-12 cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is further substituted with one or more R 49 groups.

31 . The method of claim 18 , wherein R 49 is selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-3 alkyl, C 1-3 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —NR 53 R 53 , —C(O)OR 54 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , —C(O)NR 53 R 53 , and —C(O)R 54 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-6 membered cycloalkyl is optionally substituted with —CN or one or more halo.

32 . The method of claim 18 , wherein R 43 is selected from the group consisting of: —H, halo, —CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 54 ,and —NO 2 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and 5-10 membered heteroaryl is further substituted with one or more R 49 groups.

33 . The method of claim 32 , wherein R 49 is selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —C(O)OR 54 , —S(O) 0-2 R 54 , —S(O) 1-2 NR 53 R 53 , and —C(O)R 54 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, and 3-6 membered cycloalkyl is optionally substituted with —CN or one or more halo.

34 . A method of treating a metabolic disorder comprising administering to a patient in need thereof, an effective amount of a compound of Formula IV:

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, wherein:

Q is —S(O) 2 —;

R 61 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —NR 73 R 73 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is optionally further substituted with one or more R 71 groups;

R 71 is selected from the group consisting of: hydroxyl, oxo, halo, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —P(O)R 74 R 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —SH, —S(O) 0-2 R 74 , —S(O) 1-2 NR 73 R 73 , —SF 5 , —NO 2 , —NR 73 R 73 , —NR 73 SO 2 R 74 , —OS(O) 2 R 74 , —C(O)OR 74 , —C(O)R 74 , —NR 73 C(O)OR 74 , —NR 73 C(O)NR 73 R 73 , NR 73 S(O) 2 NR 73 R 73 , and —C(O)NR 73 R 73 , wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 69 groups;

each R 69 is independently selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —NR 73 R 73 , —NR 73 C(O)OR 74 , —OS(O) 2 R 74 —C(O)OR 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —SH, —S(O) 0-2 R 74 , —S(O) 1-2 NR 73 R 73 , —C(O)NR 73 R 73 , —NR 73 SO 2 R 74 , —C(O)R 74 , —NR 73 C(O)NR 73 R 73 , —NR 73 S(O) 2 NR 73 R 73 , —SF 5 , and —NO 2 , wherein each of the C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 76 groups;

each R 73 is independently selected from the group consisting of —H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl is optionally substituted with one or more R 75 groups;

each R 74 is independently selected from the group consisting of: C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 6-10 membered aryl, 4-12 membered heterocyclyl and 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl is optionally substituted with one or more R 75 groups;

each R 75 is independently selected from —H, halo, —CN, —OH, oxo, —NO 2 , —SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —S(O)(NH)R 76 , —S(O)(NR 68 )R 76 , —S(O)(NH)NR 76 R 76 , —S(O)(NR 68 )NR 76 R 76 , —SH, —S(O) 0-2 R 76 , —S(O) 2 NH 2 , —NH 2 , S(O) 2 NR 76 R 76 , C(O)R 76 , C(O)NR 76 R 76 , and —C(O)OR 76 , wherein each of the 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with one or more R 76 groups;

each R 76 is independently selected from halo, —CN, —OH, —NH 2 , oxo, —NO 2 , —SF 5 , C 1-3 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, thioalkyl, thiohaloalkyl, thiocycloalkyl, sulfonylalkyl, sulfonylhaloalkyl, sulfonylcycloalkyl, 3-6 membered cycloalkyl, —C(O)NH 2 and —S(O) 2 NH 2 ;

R 62 is selected from the group consisting of: —H, —CN, —F, —Cl, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 heteroalkyl, C 1-3 alkoxy and C 1-3 haloalkoxy;

each R 63 and R 64 is independently selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —SH, —NR 73 R 73 , —NR 73 SO 2 R 74 , —NR 73 S(O) 2 NR 73 R 73 , —NR 73 C(O)NR 73 R 73 , —NR 73 C(O)OR 74 , tri-C 1-4 alkylsilyl, —C(O)R 74 , —C(O)OR 74 , —C(O)NR 73 R 73 and —NO 2 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally further substituted with one or more R 69 groups;

wherein R 62 and R 63 , or R 63 and R 64 can optionally join, together with the atoms to which they are attached, to form a 5-6 membered cycloalkyl, a 5-6 membered heterocyclyl, phenyl, or a 5-6 membered heteroaryl, each such cyclic groups respectively fused to the phenyl to which they are attached, and each optionally substituted with one or more R 69 groups;

R 67 is selected from the group consisting of: —H, halo, —CN, —OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-12 membered cycloalkyl, —S(O) 0-2 R 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —SH, —NR 73 R 73 , —P(O)R 74 R 74 , —C(O)OH, —C(O)OR 74 , —C(O)NR 73 R 73 , —S(O) 2 NR 73 R 73 , —C(O)R 74 , 6-10 membered aryl, 5-10 membered heteroaryl and 4-12 membered heterocyclyl; wherein each of said 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, tri-C 1-4 alkylsilyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-12 membered cycloalkyl is optionally substituted with one or more R 75 ;

R 61 is selected from the group consisting of C 1-6 alkyl, —C(O)R 74 , 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 4-12 membered heterocyclyl, —C(O)OR 74 , —C(O)NR 73 R 73 , and —SO 2 R 74 , wherein each of the C 1-6 alkyl, 3-12 membered cycloalkyl, C 1-6 heteroalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, and 4-12 membered heterocyclyl is optionally substituted with halo, —CN, oxo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, —S(O) 1-2 R 74 , —S(O) 2 NR 73 R 73 , —NO 2 , —SF 5 , C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, —NR 73 R 73 , —C(O)OR 74 , C 1-6 heteroalkyl, 3-6 membered cycloalkyl optionally substituted with R 76 , 4-12 membered heterocyclyl optionally substituted with one or more R 76 , or 6-10 membered aryl optionally substituted with one or more R 76 , and 5-10 membered heteroaryl optionally substituted with one or more R 76 .

35 . The method of claim 34 , wherein R 61 is selected from the group consisting of: C 1-6 alkyl, —NR 73 R 73 , 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl, wherein each of the C 1-6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C 3-12 cycloalkyl, and 4-12 membered heterocyclyl is further substituted with one or more R 71 groups.

36 . The method of claim 34 , wherein R 62 is selected from the group consisting of: —H, —CN, —F, methyl, C 1 haloalkyl, C 1-3 heteroalkyl, methoxy and C 1 haloalkoxy.

37 . The method of claim 36 , wherein R 62 is selected from the group consisting of: —H and —F.

38 . The method of claim 34 , wherein R 64 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, —SF 5 , —S(O) 0-2 R 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —NR 73 R 73 , —NR 73 SO 2 R 74 , —NR 73 S(O) 2 NR 73 R 73 , —NR 73 C(O)NR 73 R 73 , —NR 73 C(O)OR 74 , —C(O)R 74 , —C(O)OR 74 , —C(O)NR 73 R 73 , and —NO 2 , wherein said C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl is further substituted with one or more R 69 groups.

39 . The method of claim 38 , wherein R 64 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —S(O) 0-2 R 74 , —SF 5 , —NO 2 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F and R 74 is selected from the group consisting of C 1-6 alkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, wherein the C 1-6 alkyl, C 1-6 hydroxyalkyl, and C 1-6 heteroalkyl, is optionally substituted with one or more R 75 groups, and R 75 is independently selected from the group consisting of: halo, —CN, —OH, and oxo.

40 . The method of claim 39 , wherein R 64 is selected from the group consisting of: —H, —F, —Cl, —OH, —CN, —SR 74 , —SF 5 , C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more —F, and R 74 is C 1-3 haloalkyl.

41 . The method of claim 34 , wherein R 63 is selected from the group consisting of: —H, halo, —OH, —CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-12 cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 74 , —S(O)(NH)R 74 , —S(O)(NR 68 )R 74 , —S(O)(NH)NR 73 R 73 , —S(O)(NR 68 )NR 73 R 73 , —NR 73 R 73 , —NR 73 SO 2 R 74 , —NR 73 S(O) 2 NR 73 R 73 , —NR 73 C(O)NR 73 R 73 , —NR 73 C(O)OR 74 , —C(O)R 74 , —C(O)OR 74 , —C(O)NR 73 R 73 , and —NO 2 , wherein C 1-6 alkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, C 3-12 cycloalkyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl is further substituted with one or more R 69 groups.

42 . The method of claim 34 , wherein R 69 is selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-3 alkyl, C 1-3 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —NR 73 R 73 , —C(O)OR 74 , —S(O) 0-2 R 74 , —S(O) 1-2 NR 73 R 73 , —C(O)NR 73 R 73 , and —C(O)R 74 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, C 1-6 hydroxyalkyl, C 1-6 heteroalkyl, and 3-6 membered cycloalkyl is optionally substituted with —CN or one or more halo.

43 . The method of claim 41 , wherein R 63 is selected from the group consisting of: —H, halo, —CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, 5-10 membered heteroaryl, —SF 5 , —S(O) 0-2 R 74 ,and —NO 2 , wherein said C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and 5-10 membered heteroaryl is further substituted with one or more R 69 groups.

44 . The method of claim 42 , wherein R 69 is selected from the group consisting of: —H, oxo, —OH, —CN, halo, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, 3-6 membered cycloalkyl, —C(O)OR 74 , —S(O) 0-2 R 74 , —S(O) 1-2 NR 73 R 73 , and —C(O)R 74 , wherein each of the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 hydroxyalkyl, C 1-6 heteroalkyl, and 3-6 membered cycloalkyl is optionally substituted with —CN or one or more halo.

45 . The method of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

46 . The method of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

47 . The method of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

48 . The method of claim 1 wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

49 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

50 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

51 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

52 . The method of claim 1 , wherein the metabolic disorder is selected from the group consisting of diabetes, metabolic syndrome, dyslipidemia, obesity, insulin resistance, elevated serum cholesterol, and elevated triglycerides.

53 . The method of claim 52 , wherein the metabolic disorder is diabetes.

54 . The method of claim 53 , wherein diabetes is type I diabetes or type II diabetes.

55 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

56 . The method of claim 49 , wherein the metabolic disorder is selected from the group consisting of diabetes, metabolic syndrome, dyslipidemia, obesity, insulin resistance, elevated serum cholesterol, and elevated triglycerides.

57 . The method of claim 50 , wherein the metabolic disorder is selected from the group consisting of diabetes, metabolic syndrome, dyslipidemia, obesity, insulin resistance, elevated serum cholesterol, and elevated triglycerides.

58 . The method of claim 51 , wherein the metabolic disorder is selected from the group consisting of diabetes, metabolic syndrome, dyslipidemia, obesity, insulin resistance, elevated serum cholesterol, and elevated triglycerides.

59 . The method of claim 55 , wherein the metabolic disorder is selected from the group consisting of diabetes, metabolic syndrome, dyslipidemia, obesity, insulin resistance, elevated serum cholesterol, and elevated triglycerides.

Assignments (3)
CHANGE OF NAME Recorded Jul 16, 2024
From: THE LIVER COMPANY INC.
To: ORSOBIO, INC.
Reel/Frame 068404/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: FARAND, JULIE; KAPLAN, JOSHUA A.; NOTTE, GREGORY; OLEN, CASEY LOCKWOOD; SANGI, MICHAEL; SPERANDIO, DAVID
To: GILEAD SCIENCES, INC.
Reel/Frame 067764/0304 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: GILEAD SCIENCES, INC.
To: THE LIVER COMPANY INC.
Reel/Frame 067764/0312 →
Continuity (4)
Continuation 17463011 · Aug 31, 2021
Division 16415787 · May 17, 2019
Provisional Application 62674981 · May 22, 2018
Related Publication 20240409508A1 · Dec 12, 2024
References Cited (109)
US 9464044B2 · Ahn et al. · 2016 [cited by applicant]
US 9708316B2 · Fink et al. · 2017 [cited by applicant]
US 11136290B2 · Farand et al. · 2021 [cited by applicant]
US 12049439B2 · Farand · 2024 [cited by examiner]
US 20070072911A1 · Avolio et al. · 2007 [cited by applicant]
US 20070293547A1 · Molteni et al. · 2007 [cited by applicant]
US 20100184598A1 · Selles et al. · 2010 [cited by applicant]
US 20100227809A1 · Wolpe et al. · 2010 [cited by applicant]
US 20110288074A1 · Schann et al. · 2011 [cited by applicant]
US 20140323730A1 · Dow et al. · 2014 [cited by applicant]
US 20150210635A1 · Ahn et al. · 2015 [cited by applicant]
US 20150291563A1 · Park et al. · 2015 [cited by applicant]
US 20170226053A1 · Gauvry et al. · 2017 [cited by applicant]
US 20190359565A1 · Farand et al. · 2019 [cited by applicant]
US 20200397807A1 · Pranesh et al. · 2020 [cited by applicant]
US 20210147398A1 · Gege et al. · 2021 [cited by applicant]
US 20220055985A1 · Farand et al. · 2022 [cited by applicant]
CN 104903290A · 2015 [cited by applicant]
DE 19642451A1 · 1998 [cited by applicant]
EP 0244697A2 · 1987 [cited by applicant]
EP 0535926A1 · 1993 [cited by applicant]
EP 2865664A1 · 2015 [cited by applicant]
JP 2005126374A · 2005 [cited by applicant]
JP 2007500232A · 2007 [cited by applicant]
JP 2015525238A · 2015 [cited by applicant]
JP 2018500388A · 2018 [cited by applicant]
TW 202003457A · 2020 [cited by applicant]
WO WO0218335A1 · 2002 [cited by applicant]
WO WO2005034941A1 · 2005 [cited by applicant]
WO WO2005085188A2 · 2005 [cited by applicant]
WO WO2008049047A2 · 2008 [cited by applicant]
WO WO2008119657A1 · 2008 [cited by applicant]
WO WO2010144452A1 · 2010 [cited by applicant]
WO WO2016033341A1 · 2016 [cited by applicant]
WO WO2016081599A1 · 2016 [cited by applicant]
WO WO2016106266A1 · 2016 [cited by applicant]
WO WO2016207217A1 · 2016 [cited by applicant]
WO WO2017201313A1 · 2017 [cited by applicant]
WO WO2019226490A1 · 2019 [cited by applicant]
WO WO2023090411A1 · 2023 [cited by applicant]
Paschos (“Non-alcoholic fatty liver disease and metabolic syndrome” Hippokratia, 2009, p. 9) (Year: 2009). [cited by examiner]
Abulizi et al. “A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice”, FASEB J. (2017); 31(7):2916-2924. [cited by applicant]
Attie, K. M., et al., “Increased lean mass and muscle volume in healthy post-menopausal women treated with ACE-031 (Soluble activin type IIB receptor), an inhibitor of myostatin and other negative regulators of muscle,”… [cited by applicant]
Aurora Fine Chemicals. https://aurorafinechemicals.com/about.html, downloaded on Jul. 16, 2020 (Year: 2020), 1 page. [cited by applicant]
Aurora Fine Chemicalss. http://online.aurorafinechemicals.com/StrSearch-new.asp?S2=&R 1 =&C 1 =&C2=&C3=ON&C4=ON&R2=V2& T1 =70& T2= 1 00&mol In =&B1 =Search&N DISPLAY=20&ALLFIELDS=K24.833.925, downloaded on Jul. 16, 2020… [cited by applicant]
Bakir, F., et al. “Discovery and Structure-activity Relationship Studies of Indole Derivatives as Liver X Receptor (LXR) Agonists”, Bioorganic & Medicinal Chemistry Letters, (2007); 17(12):3473-3479. [cited by applicant]
CAS RN: 1831652-45-9; STN Entry Date: Dec. 17, 2015; Benzamide, 5-(acetylamino)-N-8-azabicyclo[3.2.1]oct-3-yl-2-[(methylsulfonyl)amino], 1 page. [cited by applicant]
CAS RN: 1831652-46-0; STN Entry Date: Dec. 17, 2015; Benzamide, 5-(acetylamino)-N-8-azabicyclo[3.2.1]oct-3-yl-2-[(methylsulfonyl)amino]-hydrochloride, 1 page. [cited by applicant]
Childress, E.S., et al., “Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential,” Journal of Medicinal Chemistry, Jun. 14, 2018, vol. 61(11), pp. 4641-4655. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2030852-21-0:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2039648-43-4:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2177727-62-5:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2188864-14-2:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2192710-60-2:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2196006-39-8:Abstract, 1 page. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service (2018) Retrieved from STN Database Accession No. 2196723-55-2:Abstract, 1 page. [cited by applicant]
Database STN, CAS Registry No. 1005134-02-1 “Benzamide, N-bicyclo[2.2.I]hept-2-yl-2-[[(4-methylphenyl)sulfonyl]amino]-”, Chemical Abstracts Service, American Chemical Society; entered Feb. 22, 2008; retrieved Jan. 5, 20… [cited by applicant]
Database STN, CAS Registry No. 1586726-38-6, “2-Naphthalenecarboxamide, N-8-azabicyclo[3.2.1 ]oct-3-yl-3-[(2-thienylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered … [cited by applicant]
Database STN, CAS Registry No. 1587020-36-7, “2-Naphthalenecarboxamide, N-8-azabicyclo[3.2.1]oct-3-yl-3-[(2-thienylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Apr. 18, 2014; retriev… [cited by applicant]
Database STN, CAS Registry No. 1587469-78-0, “Benzamide, N-8-azabicyclo[3.2.1]oct-3-yl-4-chloro-2-[(phenylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered Apr. 21, 2… [cited by applicant]
Database STN, CAS Registry No. 1587784-96-0, “Benzamide, N-8-azabicyclo[3.2.1]oct-3-yl-4-chloro-2-[(phenylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Apr. 21, 2014; retrieved Sep. 1… [cited by applicant]
Database STN, CAS Registry No. 1940909-44-3, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-5-chloro-2-[(methylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Jun. 28, 2016; retrieved Se… [cited by applicant]
Database STN, CAS Registry No. 1940909-45-4, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-5-chloro-2-[(methylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered Jun. 2… [cited by applicant]
Database STN, CAS Registry No. 1941000-63-0, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-5-methyl-2-[(methylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Jun. 28, 2016; retrieved Se… [cited by applicant]
Database STN, CAS Registry No. 1944761-47-0, “Benzamide, N-3-oxaspiro[5.5]undec-9-yl-2-[(propylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Jul. 4, 2016; retrieved Sep. 15, 2022; 3 p… [cited by applicant]
Database STN, CAS Registry No. 2030852-20-9, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-5-fluoro-2-[(methylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Nov. 14, 2016; retrieved Se… [cited by applicant]
Database STN, CAS Registry No. 2036868-49-0, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-2-[(ethylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered Nov. 24, 2016; r… [cited by applicant]
Database STN, CAS Registry No. 2038970-86-2, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-2-[(propylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Nov. 27, 2016; retrieved Sep. 15, 20… [cited by applicant]
Database STN, CAS Registry No. 2038970-87-3, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-2-[(propylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered Nov. 27, 2016; … [cited by applicant]
Database STN, CAS Registry No. 2039648-42-3, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-2-[(methylsulfonyl)amino]-”, Chemical Abstracts Service, American Chemical Society; entered Nov. 28, 2016; retrieved Sep. 15, 20… [cited by applicant]
Database STN, CAS Registry No. 1941000-64-1, “Benzamide, N-(3-aminobicyclo[3.3.1]non-9-yl)-5-methyl-2-[(methylsulfonyl)amino]-, hydrochloride (1:1)”, Chemical Abstracts Service, American Chemical Society; entered Jun. 2… [cited by applicant]
De Moura, Michelle Barbi, et al., “Mitochondrial dysfunction in neurodegenerative diseases and cancer”, Environmental and Molecular Mutagenesis (2010); 51(5):391-405. [cited by applicant]
Extended European Search Report for EP Application No. 18180450.1, mailed Nov. 22, 2018, 8 pages. [cited by applicant]
Foster “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci. (1984); 5(12):524-527. [cited by applicant]
Goedeke, et al., “Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates,” Science Translation Medicine, 2019, 11(512): eaay0284, 18 pages. [cited by applicant]
Goedeke, L., et al., “Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes,” Annual Review of Pharmacology and Toxicology, 2019, 59:65-87. [cited by applicant]
Guo, T., et al., “Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy,” Diabetes, Oct. 2012, vol. 61(10), pp. 2414-2423, doi: 10.2337/db11-0915. [cited by applicant]
Hartman et al. “Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus”, Vascular Medicine, (2014); 19(1):67-74. [cited by applicant]
International Preliminary Report on Patentability dated Nov. 24, 2020, for PCT/US2019/032925, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2019/067351, dated Aug. 12, 2019, 5 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/032925, dated Jul. 19, 2019, 13 pages. [cited by applicant]
Kauppi, Anna M. et al. “Inhibitors of type III secretion in Yersinia: Design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides” Bioorganic & Medicinal Chemistry (2007), 15(22):6994-7011. [cited by applicant]
Kim, J., et al., “Ruthenium-Catalyzed Direct C—H Amidation of Arenes Including Weakly Coordinating Aromatic Ketones,” Chemistry—A European Journal, (2013); 19(23):7328-7333. [cited by applicant]
Kim, Jeong-A., et al., “Role of Mitochondrial Dysfunction in Insulin Resistance,” Circulation Research (2008); 102(4):401-414. [cited by applicant]
Perry, R.J., et al.; “Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats,” Science 2015, 347(6227):1253-1256, with Supplementary Material, 34 pages. [cited by applicant]
Perry, R.J., et al., “Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler” Cell Metabolism 2013, 18, pp. 740-748, including Supporting Information. [cited by applicant]
RN 1005134-02-0 and RN 1005178-70-0 (both publicly available in 2008) (Year: 2008), 1 page. [cited by applicant]
RN: 2216852 37 6 to RN: 313373 56 7 all 35 compounds, Database Registry [Online] Retrieved from STN, Apr. 22, 2018, 20 pages. [cited by applicant]
Ruas et al. “Underestimation of the maximal capacity of the mitochondrial electron transport system in oligomycin-treated cells”, PLoS One, (2016); 11(3):e0150967, 20 pages. [cited by applicant]
Sci Finder entry for RN 2036868-48-9, downloaded on Jul. 16, 2020 (Year: 2020), 1 page. [cited by applicant]
Shrestha et al. “Exploring the therapeutic potential of mitochondrial uncouplers in cancer”, Molecular Metabolism, (2021); 51:101222, 20 pages. [cited by applicant]
Shulman, Gerald I., “Cellular mechanisms of insulin resistance”, The Journal of Clinical Investigation (2000); 106(2):171-176. [cited by applicant]
Shum, M., et al., “Mitochondrial oxidative function in NAFLD: Friend or foe?” Molecular Metabolism, 2021 (50):101134, 14 pages. [cited by applicant]
Sreenivasa, G.M., et al. “Synthesis and Characterization of 2-Benzene Sulphonamido-N(2′-Benzothiazolyl 6′-Fluoro-7′-Substituted) Benzamide and 2-(2-Phenyl-4-Benzylidenyl-5-Oxo-Imidazolin-1-yl) N-(2′-Amino (1′, 3′) Benzo… [cited by applicant]
STN file for RN 2036868-48-9, publicly available since Nov. 24, 2016 (Year: 2016), 1 page. [cited by applicant]
Tai, S., et al., “PC3 is a Cell Line Characteristic of Prostatic Small Cell Carcinoma,” The Prostate, 2011 (71), p. 1668-1679. [cited by applicant]
Tanko L.B. “Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?” Calcified Tissue International, (2016); 99(3):310-321. [cited by applicant]
Wang, S., “STN Search Report,” 2023. 7 pages. [cited by applicant]
Younossi, Zobair M., et al., “Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology (2016); 64(1):73-84. [cited by applicant]
Yu, R., et al. “Palladium-Catalyzed Sequential Vinylic C—H Arylation/Amination of 2- Vinylanilines with Aryl boronic Acids: Access to 2-Arylindoles,” Journal of Organic Chemistry, (2018); 83(1):323-329. [cited by applicant]
Capozzi, M.E., et al.; “Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes,” Endocr Rev.; 39(5):719-738 (Oct. 2018). [cited by applicant]
Christoffersen, B. Ø., et al., “Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss,” Obesity (Silver Spring) Apr. 2022, 30(4):841-857; doi: 10… [cited by applicant]
Deng, Y., et al.; “Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device—An Open Label Placebo Controlled Acute Study,” Obes Open Access; 3(2); pp. 1-5 (Jun. … [cited by applicant]
Kountouri, A., et al.; “Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center,” Int J Mol Sci.; 24(15):12045; pp. 1-17 (Jul. 2023). [cited by applicant]
Müller, T.D., et al., “Revisiting energy expenditure: how to correct mouse metabolic rate for body mass,” Nat Metab.; 3(9):1134-1136 (Sep. 2021). [cited by applicant]
PCT Application No. PCT/US2025/033423, International Search Report and Written Opinion mailed Oct. 9, 2025, Applicant OrsoBio, Inc., et al.; 20 pages. [cited by applicant]
Vijayakumar, A., et al.; “849-P: Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats,” Diabetes 2023; 72(Supplement_1):849-P; [Retrieved online Aug. 12, 2025] URL:https://diabetesjournals.org/diabe… [cited by applicant]
Vijayakumar, A., et al.; “899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice,” Diabetes 2024; 73(Supp… [cited by applicant]
Xian, X., et al.; “Personalized Indirect Calorimeter for Energy Expenditure (EE) Measurement,” Global Journal of Obesity Diabetes and Metabolic Syndrome 2(1):004-008 (Mar. 2015). [cited by applicant]